The addition of tafasitimab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase 3 trial presented at the 66th ASH Annual Meeting.
Ann Honeycutt, MSN, Executive Director of the Virginia Cardiovascular Specialist group, describes her experience building an ASC, the VCS Heart and Vascular Center, that first…
The active ingredient in Journavx is suzetrigine, a sodium channel blocker.
Major Finding: Cancer cells transfer mitophagy-resistant mitochondria to tumor-infiltrating lymphocytes (TIL) that impair antitumor activity. Concept: Deubiquitinase USP30 protects cancer cell-derived mitochondria from ROS-induced mitophagy…
Abstract. Tumors utilize various mechanisms of HLA disruption in order to evade immune surveillance. Previous computational tools have interrogated specific aspects of this process, yet…
Alvaro Alencar, MD, discusses the preliminary efficacy and safety of NX-5948, a BTK degrader, in patients with chronic lymphocytic leukemia.
Ashraf Z. Badros, MB, ChB, discusses the next steps following the phase 3 AURIGA trial of daratumumab and lenalidomide vs lenalidomide maintenance in patients with…
The diagnostic accuracy of radiologists aided by the eyonis LCS AI software was greatly improved compared with when radiologists were unaided.
(Cancer Cell 40, 88–102; January 10, 2022)
wednesday, february 26 continental breakfast 7-8 a.m. Keynote Session 4 8-8:30 a.m. Session Chair: Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California education…
